Medical/Pharmaceuticals
WuXi AppTec Issues Positive Profit Alert for the Full Year of 2025
SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today issued a Positive Profit Alert for the full year of 2025, disclosing forecasts of key operational data...
2026-01-12 17:30
10217
Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
TAIPEI, Jan. 12, 2026 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil Pharmaceuticals, Co., Ltd ("Samil", 000520.KS), for exclusive rights to the commercialization of clobetasol...
2026-01-12 16:00
10604
Clover Initiates Phase 2 Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
-- Phase 2 Initiation Strengthens Global First-in-Class Potential for Clover's
Protein-Based RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates --
SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
2026-01-12 12:33
613
Zylox-Tonbridge Hosts Investor Open Day, Showcasing Innovation Pipeline and Global Growth Strategy
HANGZHOU, China, Jan. 11, 2026 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190), a leading innovator in neurovascular and peripheral vascular interventional solutions, hosted its Investor Open Day at its Zhuhai Innovation Center, welcoming nearly 150 institutional investo...
2026-01-12 12:16
9489
Nona Biosciences Enters into Collaboration Agreement with Link Cell Therapies to Advance CAR-T Cell Therapies
CAMBRIDGE, Mass., Jan. 9, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery through innovative technology platforms, today announced that it has entered into a multi-target antibody discovery collaboration with Link Cell Therapies. This c...
2026-01-09 20:00
8461
Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
SAN FRANCISCO and SUZHOU, China, Jan. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...
2026-01-09 08:00
8667
MediLink Has Signed an Additional Exclusive Licensing Agreement with Roche
SUZHOU, China, Jan. 8, 2026 /PRNewswire/ -- MediLink Therapeutics ("MediLink") today announced that it has entered into a new collaboration and exclusive licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the development and commercialization of YL201, an investigational novel antib...
2026-01-09 08:00
6963
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
SYDNEY, Jan. 8, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer,John Friend, MD, will be in San Francisco next week to participate in meetings during the annual J.P. Morgan Healthcare Conference week (JPM Week). During the week, Kazia will ...
2026-01-08 22:00
9515
Chinese Medical AI Team's MedGPT Tops Global Rankings in New Clinical Benchmark Published by Nature Portfolio Journal
BEIJING, Jan. 8, 2026 /PRNewswire/ -- A research team from China has introduced the first standardized framework for evaluating the clinical applicability of medical AI systems, with their findings published in npj Digital Medicine, a leading journal in the Nature Portfolio ranked in the top tier...
2026-01-08 14:51
6982
Arbele Receives FDA Orphan Drug Designation for ARB1002, an Anti-CDH17 Antibody-Drug Conjugate for the Treatment of Pancreatic Cancer
SEATTLE, Jan. 7, 2026 /PRNewswire/ -- Arbele, a biotechnology company focused on developing innovative targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ARB1002, its investigational antibody-drug conjugate (ADC...
2026-01-08 00:00
6747
Sensura to Showcase Non-Invasive Health Monitoring Platform, Starting with Glucose, at CES 2026
LAS VEGAS, Jan. 6, 2026 /PRNewswire/ -- Sensura, a Singapore-based deep-tech company focused on next-generation health and wellness monitoring, today announced that it will showcase its non-invasive health monitoring platform, starting with glucose, atCES 2026, taking place from January 6–9, 2026...
2026-01-07 11:18
10260
Ivonescimab's Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study
HONG KONG, Jan. 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update inChina for its internally developed, first-in-class PD-1/VEGF bispecific antibody, ivonescimab. The updated label incorporates final a...
2026-01-07 10:50
8659
Kelun-Biotech to Attend the 44th J.P. Morgan Healthcare Conference, Sharing Its Business Progresses and Innovation Strategies
CHENGDU, China, Jan. 6, 2026 /PRNewswire/ -- The 44th J.P. Morgan Healthcare Conference (JPMHC) will be held inSan Francisco, California, USA, from January 12 to 15, 2026. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) has been invited to attend the ...
2026-01-07 10:44
12369
HealthBiome Achieves Dual Regulatory Milestones: FDA NDI Acknowledgment and Korean MFDS Approval for HB05P Muscle Health Ingredient
Akkermansia muciniphila postbiotic receives both U.S. FDA dietary supplement clearance and Korean functional ingredient approval with muscle health claim, positioning HealthBiome for dual-market launch in 2026 DAEJEON, South Korea, Jan. 6, 2026 /PRNewswire/ -- HealthBiome Inc., a pioneering stri...
2026-01-07 08:00
10538
Celltrion to present at the 44th Annual J.P. Morgan Healthcare Conference
INCHEON, South Korea, Jan. 6, 2026 /PRNewswire/ -- Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today announced that Jin-Seok Seo, Chief Executive Officer andHyuk-Jae Lee, Senior Executive Vice President at Celltrion, will present at the 44th Annual J.P. Morgan Healthc...
2026-01-07 07:42
13990
Nuon Medical Unveils Tech-Integrated Packaging Ecosystem at CES 2026, Engineering Clinical Precision into the Point of Skin Contact
LAS VEGAS, Jan. 6, 2026 /PRNewswire/ -- Nuon Medical, a leader in beauty tech
innovation, has announced a comprehensive tech-integrated packaging ecosystem
at CES 2026.
2026-01-07 01:00
613
Mind With Heart Robotics Showcases Emotionally Intelligent Robot Lineup at CES 2026, Including CES Innovation Award Honoree An'An Biomimetic Affective AI Panda
Company Expands Therapeutic Robotics Comprehensive Product Lineup Addressing Diverse Emotional and Clinical Support Needs LAS VEGAS, Jan. 6, 2026 /PRNewswire/ -- Mind With Heart Robotics Co., Ltd. showcases its comprehensive lineup of emotionally intelligent robots that mimic natural movements, ...
2026-01-07 01:00
1597
Expanding Healthcare Access for Women's Health -- Noul Unveils AI-Automated Cervical Cancer Diagnostics Solution at CES 2026
* Dramatically cuts diagnostic workflows by 80%…delivering results in under 20 minutes * Decentralized, fully automated diagnostic model helps reduce healthcare infrastructure gaps and supports WHO's 2030 cervical cancer screening goals * Eco-friendly, sustainable AI diagnostics with NGSI so...
2026-01-07 01:00
766
VivaVision Biotech Receives Positive Written Feedback from FDA - VVN461HD New Drug Application (NDA) Requires Only a "Single Phase III" Pivotal Clinical Study in the U.S. for Non-Infectious Anterior Uveitis Treatment
WENZHOU, China, Jan. 6, 2026 /PRNewswire/ -- Recently, VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs, announced that it has received the written meeting minutes from the U.S. Food and Drug Administration (F...
2026-01-07 00:00
588
Bambusa Therapeutics Announces First Patient Dosed in Phase Ib Proof-of-Concept COPD Study of BBT002, Reinforcing Bispecific Pipeline Momentum
BOSTON, Jan. 6, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc., a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology & inflammation (I&I), today announceddosing of the first patient in the Phase Ib clinical trial of BBT002, a novel platform-in-a...
2026-01-06 22:30
2555
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 315 media titles]
2026-08-28 09:01Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
[Picked up by 314 media titles]
2026-08-27 10:25
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 308 media titles]
2026-09-02 08:30Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 307 media titles]
2026-09-02 12:17
Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 302 media titles]
2026-09-01 11:00
Most Read
Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
2026-08-27 10:25
17339